Ana Oaknin, MD

Ana Oaknin, MD, principal investigator, Gynecological Malignancies Group, Vall d’Hebron Institute of Oncology, head of Gynecologic Tumors Unit, senior medical oncologist and attending physician, Medical Oncology Department, Vall d’Hebron University Hospital, discusses the rationale for the phase I/II GARNET trial in endometrial cancer.

Ana Oaknin, MD, principal investigator, Gynecological Malignancies Group, Vall d’Hebron Institute of Oncology, head of Gynecologic Tumors Unit, senior medical oncologist and attending physician, Medical Oncology Department, Vall d’Hebron University Hospital, discusses the safety profile of dostarlimab (TSR-042) in patients with endometrial cancer.

Ana Oaknin, MD, principal investigator, Vall d’Hebron Institute of Oncology, Gynecological Malignancies Group, head of Gynecologic Tumors Unit, Medical Oncology Department, Vall d’Hebron University Hospital, discusses findings of the GARNET study in endometrial cancer.

Ana Oaknin, MD, principal investigator, Vall d’Hebron Institute of Oncology, Gynecological Malignancies Group, head of Gynecologic Tumors Unit, Medical Oncology Department, Vall d’Hebron University Hospital, discusses the phase I/II GARNET trial in patients with endometrial cancer.